Easeng Holdings Easeng Holdings

About Us

Company Profile

Beijing Easeng Holdings Co., Ltd. is a cell and gene therapy (CGT) research and development company. Its two product areas are personalized neoantigen DC therapeutic vaccines and innovative exosome therapeutics. The company has capabilities in cell research, algorithm development, experimental validation, process development, quality control and clinical collaboration, supported by a complementary full-time team covering key steps from research through industrialization.

Leadership

A full-time, multidisciplinary leadership team

Milestones

Advancing research and clinical translation

  1. 2021

    1. Beijing Easeng Holdings Co., Ltd. (formerly Beijing Easeng Medical Technology Co., Ltd.) was incorporated

  2. 2022

    1. Clean laboratory commenced operations

    2. Recognized as a Zhongguancun High-Tech Enterprise

  3. 2023

    1. Obtained first Class II medical device certificate

    2. Recognized as a Zhongguancun technology-based micro and small enterprise

    3. Completed RMB 12.5 million angel financing

    4. Completed P2 biosafety laboratory filing

    5. Recognized as an Innovative SME in Beijing

    6. An ISO-aligned domestic standard on quality management of raw materials for cell therapy product manufacturing, principally drafted by the company, took effect

    7. National standard GB/T 42398-2023 on design of cleanrooms for cell culture, drafted with a company expert as lead writer, took effect

    8. High-grade serous carcinoma of the female reproductive system project passed ethics review

  4. 2024

    1. Completed replication-competent lentivirus testing service for a dual US-China filing program

    2. Aseptic liquid dressing study for acne scarring passed ethics review

    3. Approved for a 14th Five-Year Plan key R&D program

    4. Hepatocellular carcinoma project passed ethics review

    5. Obtained a medical device manufacturing license

    6. Won first prize in advanced manufacturing at the 5th Shijingshan Entrepreneurship and Innovation Competition

    7. Won first prize in the Beijing division of the University of Hong Kong International Innovation and Entrepreneurship Competition

    8. Won first prize in advanced manufacturing at the 7th Entrepreneurship Beijing competition

    9. Won second prize in advanced manufacturing at the national finals of the 6th China Chuangyi competition

    10. Named a National Outstanding Entrepreneurship Project by the Ministry of Human Resources and Social Security

    11. Approved to establish a national postdoctoral research workstation

    12. Recognized as a National High-Tech Enterprise

  5. 2025

    1. Obtained an Internet Drug Information Service Qualification Certificate

    2. Approved for a national 14th Five-Year Plan key R&D program

    3. Pancreatic cancer project passed ethics review

    4. Glioblastoma project passed ethics review

    5. Ovarian cancer project passed ethics review

  6. 2026

    1. Pancreatic ductal adenocarcinoma project passed ethics review

    2. Dry-eye project passed ethics review

    3. Dry-eye project completed national clinical research registration

    4. Prostate cancer project passed ethics review

    5. Ovarian cancer project completed national somatic cell clinical research filing

    6. Received fee approval from the Beidaihe Life and Health Industry Innovation Demonstration Zone

    7. Ovarian cancer project completed national biomedical new technology clinical research filing

    8. Signed a collaboration agreement with the National Clinical Research Center for Otolaryngologic Diseases

    9. Signed a research collaboration agreement with the Ophthalmology Department of Beijing Tongren Hospital

Group Companies

北京艺升控股有限公司
北京艺升医疗科技有限公司
北京艺升医学科技有限公司
北京艺升明瞳生物科技有限公司